167 related articles for article (PubMed ID: 1417960)
1. Depletion of a discrete nuclear glutathione pool by oxidative stress, but not by buthionine sulfoximine. Correlation with enhanced alkylating agent cytotoxicity to human melanoma cells in vitro.
Jevtović-Todorović V; Guenthner TM
Biochem Pharmacol; 1992 Oct; 44(7):1383-93. PubMed ID: 1417960
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF
Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369
[No Abstract] [Full Text] [Related]
3. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
[TBL] [Abstract][Full Text] [Related]
4. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells.
Benathan M; Alvero-Jackson H; Mooy AM; Scaletta C; Frenk E
Melanoma Res; 1992 Dec; 2(5-6):305-14. PubMed ID: 1337997
[TBL] [Abstract][Full Text] [Related]
5. The relationship between nuclear glutathione levels and resistance to melphalan in human ovarian tumour cells.
Britten RA; Green JA; Broughton C; Browning PG; White R; Warenius HM
Biochem Pharmacol; 1991 Feb; 41(4):647-9. PubMed ID: 1997012
[No Abstract] [Full Text] [Related]
6. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of human melanoma cells to melphalan cytotoxicity by adriamycin and carmustine.
Jevtović-Todorović V; Guenthner TM
J Cancer Res Clin Oncol; 1991; 117(4):313-20. PubMed ID: 2066351
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
10. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard.
Somfai-Relle S; Suzukake K; Vistica BP; Vistica DT
Biochem Pharmacol; 1984 Feb; 33(3):485-90. PubMed ID: 6704165
[No Abstract] [Full Text] [Related]
11. Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cancer cells.
Ripple M; Mulcahy RT; Wilding G
J Urol; 1993 Jul; 150(1):209-14. PubMed ID: 8510259
[TBL] [Abstract][Full Text] [Related]
12. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
Prezioso JA; FitzGerald GB; Wick MM
J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
[TBL] [Abstract][Full Text] [Related]
13. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
14. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
15. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.
Alaoui-Jamali MA; Panasci L; Centurioni GM; Schecter R; Lehnert S; Batist G
Cancer Chemother Pharmacol; 1992; 30(5):341-7. PubMed ID: 1505071
[TBL] [Abstract][Full Text] [Related]
16. Enhanced in vitro cytotoxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea or buthionine sulfoximine combined with a reactive oxygen-generating enzyme immunotoxin.
Ito H; Rousseau V; Goavec M; Beaujean F; Morizet J; Stanislawski M
Cancer Lett; 1990 Feb; 49(2):169-73. PubMed ID: 2306711
[TBL] [Abstract][Full Text] [Related]
17. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines.
Lai GM; Moscow JA; Alvarez MG; Fojo AT; Bates SE
Int J Cancer; 1991 Nov; 49(5):688-95. PubMed ID: 1682279
[TBL] [Abstract][Full Text] [Related]
18. Reversal of melphalan resistance in vivo and in vitro by modulation of glutathione metabolism.
Medh RD; Gupta V; Awasthi YC
Biochem Pharmacol; 1991 Jul; 42(2):439-41. PubMed ID: 1859455
[No Abstract] [Full Text] [Related]
19. The role of glutathione in lymphocyte activation. I. Comparison of inhibitory effects of buthionine sulfoximine and 2-cyclohexene-1-one by nuclear size transformation.
Hamilos DL; Wedner HJ
J Immunol; 1985 Oct; 135(4):2740-7. PubMed ID: 4031498
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
Thrall BD; Raha GA; Springer DL; Meadows GG
Pigment Cell Res; 1991 Dec; 4(5-6):234-9. PubMed ID: 1823927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
